Spyre Therapeutics, Inc.
Clinical trials sponsored by Spyre Therapeutics, Inc., explained in plain language.
A biotechnology company developing antibody therapies for inflammatory bowel disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug SPY002-072 aims to tame multiple inflammatory joint diseases Results expected Oct 2026 (estimated) May already have reported ↗
- New drug SPY003-207 tested in humans for first time Results expected Nov 2026 (estimated)
- New antibody cocktail aims to tame ulcerative colitis Results expected Jun 2027 (estimated) May already have reported ↗
-
First-in-Human trial aims to unlock a new Therapy's potential
Knowledge-focused CompletedThis early-stage trial is testing an experimental drug called SPY002-072 in healthy volunteers to see if it is safe and how the body handles it. Participants receive a single dose of the drug or a placebo, and researchers monitor for side effects and measure drug levels in the bl…
Phase 1 • Sponsor: Spyre Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Healthy volunteers test new drug SPY002-091 for first time
Knowledge-focused CompletedThis early-stage study tests the safety and how the body handles a new drug called SPY002-091. It involves 50 healthy adults who receive either the drug or a placebo. The main goal is to check for side effects and measure drug levels in the blood.
Phase 1 • Sponsor: Spyre Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
New drug SPY001-001 tested in healthy people for first time
Knowledge-focused CompletedThis early-phase trial tested the safety and tolerability of a new drug called SPY001-001 in 96 healthy volunteers. Participants received either the drug or a placebo, and researchers monitored side effects and how the drug moves through the body. Since this is a first-in-human s…
Phase 1 • Sponsor: Spyre Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:04 UTC